Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yishen Tiaojing Pill for premature ovarian insufficiency
ChiCTR2300070821Phase 2Not yet recruiting
- Sponsor
- Jingzhou Traditional Chinese Medicine Hospital
- Start
- May 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Yishen Tiaojing Pill in ovarian hypofunction (POI), sponsored by Jingzhou Traditional Chinese Medicine Hospital. Primary endpoints: Anti-Mullerian hormone, Follicle-stimulating hormone and 1 more. Planned start May 2023; status: not yet recruiting.
02
Drugs
Yishen Tiaojing Pill
03
Conditions
ovarian hypofunction (POI)
Beyond the preview
Go deeper on ChiCTR2300070821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070821.